At clinics where immunotherapy was practiced, only 12% used genomic sequencing to assess the tumor mutational burden biomarker, and only 44% assessed the PD-L1 biomarker, suggesting limited prediction of immunotherapy response prior to administration. This evidence concerns the gene CD274 and neoplasm.